Join
Live feed
·
PRReleasevia Quantisnow
Merck & Company Inc. logo
Moderna Inc. logo

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma

ByQuantisnow·Wall Street's wire, on your screen.
MRK· Merck & Company Inc.MRNA· Moderna Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MRK (Merck & Company Inc.), MRNA (Moderna Inc.) and more on Quantisnow.